Pathogenesis of cognitive dysfunction in phenylketonuria: review of hypotheses
- PMID: 20123477
- DOI: 10.1016/j.ymgme.2009.10.016
Pathogenesis of cognitive dysfunction in phenylketonuria: review of hypotheses
Abstract
In untreated phenylketonuria (PKU), deficiency of phenylalanine hydroxylase (PAH) results in elevated blood phenylalanine (Phe) concentrations and severe mental retardation. Current dietary treatment prevents mental retardation, but cognitive outcome remains suboptimal. The mechanisms by which elevated blood Phe concentrations disturb cerebral metabolism and cognitive function have not been fully elucidated. In this review, we discuss different hypotheses on the pathogenesis of PKU, focusing on the effects of disturbed large neutral amino acid (LNAA) transport from blood to brain on cerebral neurotransmitter and protein synthesis. Although the definitive roles of these processes in PKU pathogenesis are not fully understood yet, both substantially influence clinical outcome.
Copyright 2009 Elsevier Inc. All rights reserved.
Similar articles
-
Large Neutral Amino Acid Supplementation Exerts Its Effect through Three Synergistic Mechanisms: Proof of Principle in Phenylketonuria Mice.PLoS One. 2015 Dec 1;10(12):e0143833. doi: 10.1371/journal.pone.0143833. eCollection 2015. PLoS One. 2015. PMID: 26624009 Free PMC article.
-
Future role of large neutral amino acids in transport of phenylalanine into the brain.Pediatrics. 2003 Dec;112(6 Pt 2):1570-4. Pediatrics. 2003. PMID: 14654667
-
Brain dysfunction in phenylketonuria: is phenylalanine toxicity the only possible cause?J Inherit Metab Dis. 2009 Feb;32(1):46-51. doi: 10.1007/s10545-008-0946-2. Epub 2009 Jan 13. J Inherit Metab Dis. 2009. PMID: 19191004 Review.
-
The effects of large neutral amino acid supplements in PKU: an MRS and neuropsychological study.Mol Genet Metab. 2007 May;91(1):48-54. doi: 10.1016/j.ymgme.2007.02.002. Epub 2007 Mar 23. Mol Genet Metab. 2007. PMID: 17368065 Clinical Trial.
-
A comparison of phenylketonuria with attention deficit hyperactivity disorder: do markedly different aetiologies deliver common phenotypes?Brain Res Bull. 2013 Oct;99:63-83. doi: 10.1016/j.brainresbull.2013.10.003. Epub 2013 Oct 16. Brain Res Bull. 2013. PMID: 24140048 Review.
Cited by
-
Large neutral amino acid supplementation increases melatonin synthesis in phenylketonuria: a new biomarker.J Pediatr. 2013 May;162(5):999-1003. doi: 10.1016/j.jpeds.2012.10.015. Epub 2012 Nov 16. J Pediatr. 2013. PMID: 23164313 Free PMC article. Clinical Trial.
-
Untargeted Metabolomics for Autism Spectrum Disorders: Current Status and Future Directions.Front Psychiatry. 2019 Sep 10;10:647. doi: 10.3389/fpsyt.2019.00647. eCollection 2019. Front Psychiatry. 2019. PMID: 31551836 Free PMC article. Review.
-
Recent Advances in Understanding the Structure and Function of the Human Microbiome.Front Microbiol. 2022 Feb 3;13:825338. doi: 10.3389/fmicb.2022.825338. eCollection 2022. Front Microbiol. 2022. PMID: 35185849 Free PMC article. Review.
-
Efficacy and safety of sapropterin dihydrochloride in patients with phenylketonuria: A meta-analysis of randomized controlled trials.Br J Clin Pharmacol. 2019 May;85(5):893-899. doi: 10.1111/bcp.13886. Epub 2019 Mar 18. Br J Clin Pharmacol. 2019. PMID: 30720885 Free PMC article.
-
Dietary treatment of phenylketonuria: the effect of phenylalanine on reaction time.J Inherit Metab Dis. 2011 Apr;34(2):449-54. doi: 10.1007/s10545-010-9276-2. Epub 2011 Feb 3. J Inherit Metab Dis. 2011. PMID: 21290182
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical